Over the past few decades, research on cancer immunotherapy using immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway has achieved remarkable progress. The gene discussed is PDCD1; the disease is cancer.